ES2272771T3 - Uso de aminometil cromanos sustituidos en el tratamiento de transtornos extrapirimidales del movimiento. - Google Patents

Uso de aminometil cromanos sustituidos en el tratamiento de transtornos extrapirimidales del movimiento. Download PDF

Info

Publication number
ES2272771T3
ES2272771T3 ES02767352T ES02767352T ES2272771T3 ES 2272771 T3 ES2272771 T3 ES 2272771T3 ES 02767352 T ES02767352 T ES 02767352T ES 02767352 T ES02767352 T ES 02767352T ES 2272771 T3 ES2272771 T3 ES 2272771T3
Authority
ES
Spain
Prior art keywords
methyl
formula
dihydro
benzoisothiazol
benzopyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02767352T
Other languages
English (en)
Spanish (es)
Inventor
Gerd Bartoszyk
Hermann Russ
Christoph Seyfried
Henning Bottcher
Heinz-Hermann Bokel
Uschi Schmid-Grossmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2272771T3 publication Critical patent/ES2272771T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES02767352T 2001-09-12 2002-08-09 Uso de aminometil cromanos sustituidos en el tratamiento de transtornos extrapirimidales del movimiento. Expired - Lifetime ES2272771T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01121910 2001-09-12
EP01121910 2001-09-12

Publications (1)

Publication Number Publication Date
ES2272771T3 true ES2272771T3 (es) 2007-05-01

Family

ID=8178618

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02767352T Expired - Lifetime ES2272771T3 (es) 2001-09-12 2002-08-09 Uso de aminometil cromanos sustituidos en el tratamiento de transtornos extrapirimidales del movimiento.

Country Status (23)

Country Link
US (1) US20040235920A1 (ko)
EP (1) EP1425008B1 (ko)
JP (1) JP2005522410A (ko)
KR (1) KR100886185B1 (ko)
CN (1) CN1303996C (ko)
AR (1) AR036509A1 (ko)
AT (1) ATE341322T1 (ko)
AU (1) AU2002331220B2 (ko)
BR (1) BR0212199A (ko)
CA (1) CA2458628A1 (ko)
CY (1) CY1105868T1 (ko)
DE (1) DE60215203T2 (ko)
DK (1) DK1425008T3 (ko)
ES (1) ES2272771T3 (ko)
HU (1) HUP0401317A3 (ko)
MX (1) MXPA04002304A (ko)
MY (1) MY130522A (ko)
PL (1) PL207146B1 (ko)
PT (1) PT1425008E (ko)
RU (1) RU2320336C2 (ko)
SI (1) SI1425008T1 (ko)
WO (1) WO2003022269A1 (ko)
ZA (1) ZA200402774B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2493618A1 (en) 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
HUE031661T2 (en) * 2010-10-15 2017-07-28 Contera Pharma Aps Combinations of serotonin receptor agonists for the treatment of movement disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE9303274D0 (sv) 1993-10-07 1993-10-07 Astra Ab Novel phenylethyl and phenylproplamines
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
DE10101917A1 (de) * 2001-01-16 2002-07-18 Bayer Ag Verwendung von Chromanen

Also Published As

Publication number Publication date
MXPA04002304A (es) 2004-06-29
PT1425008E (pt) 2007-01-31
EP1425008A1 (en) 2004-06-09
DK1425008T3 (da) 2007-01-15
SI1425008T1 (sl) 2007-02-28
DE60215203D1 (de) 2006-11-16
HUP0401317A2 (en) 2004-10-28
CA2458628A1 (en) 2003-03-20
CN1555259A (zh) 2004-12-15
US20040235920A1 (en) 2004-11-25
RU2004111284A (ru) 2005-05-10
KR20040043175A (ko) 2004-05-22
HUP0401317A3 (en) 2007-05-29
MY130522A (en) 2007-06-29
AU2002331220B2 (en) 2007-06-07
EP1425008B1 (en) 2006-10-04
RU2320336C2 (ru) 2008-03-27
JP2005522410A (ja) 2005-07-28
KR100886185B1 (ko) 2009-02-27
PL369827A1 (en) 2005-05-02
AR036509A1 (es) 2004-09-15
DE60215203T2 (de) 2007-10-18
ZA200402774B (en) 2005-01-13
BR0212199A (pt) 2004-10-05
ATE341322T1 (de) 2006-10-15
WO2003022269A1 (en) 2003-03-20
PL207146B1 (pl) 2010-11-30
CY1105868T1 (el) 2011-02-02
CN1303996C (zh) 2007-03-14

Similar Documents

Publication Publication Date Title
US8030314B2 (en) Use of 2h-benzimidazol-2-one, 1,3-dihydro-1-(2{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)-and its physiologically acceptable acid addition salts
ES2602973T3 (es) Combinaciones de agonistas del receptor de serotonina para el tratamiento de trastornos del movimiento
JP2008519847A (ja) 運動障害の治療方法
CN107660147B (zh) 用于治疗帕金森病和相关障碍的组合物
ES2966929T3 (es) Tratamiento de trastornos del movimiento
US11224603B2 (en) Antihistamines in combination with a range of substances for improved health
ES2251460T3 (es) Nuevo uso de (r)-(-)-2-(5-(4-fluorfenil)-3-piridilmetilaminometil)-cromano y sus sales fisiologicamente aceptables.
ES2280602T3 (es) Uso de 2-(5-(4-fluorofenil)-3-piridilmetilaminometil)-cromano y sus sales fisiologicamente aceptables.
ES2272771T3 (es) Uso de aminometil cromanos sustituidos en el tratamiento de transtornos extrapirimidales del movimiento.
AU2002355170A1 (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
KR20090031908A (ko) Ｓｌｖ308 및 ｌ-ｄｏｐａ를 포함하는 병용 제제
AU2002331220A1 (en) Novel use of substituted aminomethyl chromans for the treatment of movement disorder and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders
ZA200401592B (en) Novel use of 2-[5- (4-fluorophenyl)-3-pyridylmethylaminomethyl} -chromane and its physiologically acceptable salts